Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTX plus Cisplatin and Irinotecan in Metastatic Pancreatic Cancer
NCT02324543Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2015
- Primary completion
- Jun 2019
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, docetaxel, capecitabine, Cisplatin micelle injection (HA132), irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in pancreatic adenocarcinoma (PDAC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Feb 2015; status: completed.
02
Drugs
gemcitabinedocetaxelcapecitabineCisplatin micelle injection (HA132)irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02324543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02324543.